Boston Scientific acquires BTG to strengthen tumor intervention and vascular disease treatment technology.

(Health Times web reporter Wei Wei)
. Recently, Boston Scientific, a U.S. medical device company, announced that it had completed its acquisition of BTG in accordance with its previously announced restructuring plan. BTG is an international medical device manufacturer and pharmaceutical company headquartered in London, UK, based in 1991, which develops and sells minimally invasive surgical products for the treatment of cancer and vascular diseases, as well as specialty drugs.
, according to Boston Science, BTG has three core businesses, the largest of which is its highly differentiated portfolio of interventional medicine, including tumor interventional therapy for patients with liver and kidney cancer, and a combination of vascular diseases for the treatment of deep vein embolism, pulmonary embolism, deep vein obstruction, and shallow vein disease."The addition of BTG's interventional medicine portfolio strengthens our leading strategy in product segmentation, enabling us to provide state-of-the-art technology, clinical evidence, and a better commercial infrastructure to support physicians in treating some of the most challenging diseases affecting the health of patients worldwide," said Ma Hongming, President and CEO of
Boston Science. By fully integrating the talent and clinical and business expertise of our two best companies, we will be able to achieve continuous innovation and medical coverage to develop disease treatment technologies in a way that cannot be achieved by a single company. In addition to the Interventional Medicine product line, the
BTG's portfolio includes a specialty drug business, which includes acute therapeutic antidotes for the treatment of overexposure of certain drugs and toxins, and licensing businesses that collect royalties associated with BTG's intellectual property rights and product licensing agreements.
btG was a wholly owned subsidiary of Boston Science when the restructuring took effect and BTG's shares were no longer traded on the London Stock Exchange.
Boston Scientific expects to complete its previously announced plan to sell its global embolic microsphere portfolio, which includes the Embozene, Embozene TANDEM and ONCOZENe brands, in due course. The transaction was made to pass the antitrust approvals required to complete the BTG acquisition.
, Boston Scientific is also in the works to launch and research the divestiture of BTG's Zytiga license agreement, which is expected to be completed by the end of 2019.according to
, Boston Science was established in the United States in June 1979. In 1997, Boston Science entered China, with branches and research centers in Beijing, Shanghai and Guangzhou, and the company's headquarters in Shanghai. Boston Scientific's core business areas in China are cardiac intervention, cardiac rhythm management and electrophysiology, structural heart disease, endoscopy intervention, breathing, peripheral and tumor intervention, and urology and women's health.
.